Spruce Biosciences Q3 2026 Earnings Date & Estimates

Spruce Biosciences (NASDAQ:SPRB) is a biotechnology company focused on developing medicines for rare endocrine disorders. The company’s research centers on conditions in which abnormal hormone production creates significant health complications and limited treatment options.

Spruce’s lead product candidate is tildacerfont, an investigational, orally administered selective corticotropin-releasing factor type 1 receptor antagonist. The therapy is designed to regulate the hypothalamic-pituitary-adrenal axis and reduce excessive adrenocorticotropic hormone and adrenal androgen production. Spruce has studied tildacerfont primarily in congenital adrenal hyperplasia, a rare inherited disorder that affects the adrenal glands, and has evaluated its potential in other endocrine-related conditions.

Spruce Biosciences has operated as a clinical-stage company serving the global biopharmaceutical and rare-disease markets. Its development programs have focused on advancing targeted treatments through clinical testing and regulatory evaluation rather than commercializing an established portfolio of products.